Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.

NCT00034619 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00034619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00034619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer